Why the study?
Acute myocarditis and pericarditis associated with SARS-CoV-2 vaccines raised public anxiety, scientific uncertainty, and vaccination obstacles, prompting the Portuguese Society of Cardiology to address key epidemiological, pathophysiological, diagnostic, and risk-benefit questions.
What is the risk, pathophysiology, and clinical management of anti-SARS-CoV-2 vaccine-induced myocarditis compared to the risk of severe COVID-19?
What is the risk, pathophysiology, and clinical management of anti-SARS-CoV-2 vaccine-induced myocarditis compared to the risk of severe COVID-19?
This consensus statement affirms that while SARS-CoV-2 vaccines can cause rare and generally mild myocarditis, the benefits of vaccination in preventing severe COVID-19 far outweigh these risks.
Answers are grounded in this paper and cite their sources.
Supports continued vaccination; confirms benefits outweigh rare myocarditis risks and guides management.
Acute myocarditis (especially) and pericarditis have been consistently associated with the administration of vaccines against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), generating anxiety in the general population, uncertainty in the scientific community and obstacles to ambitious mass vaccination programs, especially in foreign countries. Like some of its European counterparts, the Portuguese Society of Cardiology (SPC), through its Studies Committee, decided to take a position on some of the most pressing questions related to this issue: (i) How certain are we of this epidemiological association? (ii) What is the probability of its occurrence? (iii) What are the pathophysiological bases of these inflammatory syndromes? (iv) Should their diagnosis, treatment and prognosis follow the same steps as for typical idiopathic or post-viral acute myopericarditis cases? (v) Is the risk of post-vaccine myocarditis great enough to overshadow the occurrence of serious COVID-19 disease in unvaccinated individuals? In addition, the SPC will issue clinical recommendations and offer its outlook on the various paths this emerging disease may take in the future. Quadros de miocardite (sobretudo) e de pericardite agudas têm vindo a ser consistentemente relacionados com a administração das vacinas anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2), gerando ansiedade na população geral, incerteza na comunidade científica e entraves aos ambiciosos programas de vacinação maciça, sobretudo em países estrangeiros. À semelhança de algumas das suas congéneres europeias, pretende a Sociedade Portuguesa de Cardiologia (SPC), por intermédio da sua Comissão de Estudos, tomar posição em relação a algumas da questões mais prementes a si associadas: (i) Quão certos estamos desta associação epidemiológica?; (ii) Qual a probabilidade da sua ocorrência?; (iii) Quais as bases fisiopatológicas destas síndromes inflamatórias?; (iv) Deverão os seus diagnóstico, tratamento e prognóstico seguir os mesmos trâmites dos restantes casos de miopericardite aguda idiopática ou de etiologia pós-vírica?; (v) Será o risco de miocardite pós-vacinal bastante o suficiente a ponto de sobrepujar o da instalação de doença grave por Covid-19 em indivíduos não vacinados? Adicionalmente, serão avançadas recomendações clínicas e perspetivados os diversos trilhos de evolução futura, no respeitante a esta emergente entidade nosológica.
No takes yet. Share an insight, caveat, or question.
Sousa et al. (2023) conducted a review in Anti-SARS-CoV-2 vaccine-induced myocarditis and pericarditis. Anti-SARS-CoV-2 vaccines was evaluated. The Portuguese Society of Cardiology issued a consensus statement addressing the epidemiology, pathophysiology, diagnosis, and management of anti-SARS-CoV-2 vaccine-induced myocarditis.
Synapse has enriched 10 related papers. Consider them for comparative context: